Fulcrum Therapeutics (FULC) Cash from Operations (2019 - 2026)

Fulcrum Therapeutics (FULC) has disclosed Cash from Operations for 7 consecutive years, with 16798000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations changed 0.22% to 16798000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 60065000.0 through Dec 2025, down 2608.07% year-over-year, with the annual reading at 60065000.0 for FY2025, 2608.07% down from the prior year.
  • Cash from Operations for Q4 2025 was 16798000.0 at Fulcrum Therapeutics, down from 14190000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 58899000.0 in Q2 2024, with the low at 27882000.0 in Q3 2022.
  • Average Cash from Operations over 5 years is 16438800.0, with a median of 20240500.0 recorded in 2022.
  • The sharpest move saw Cash from Operations plummeted 401.18% in 2021, then soared 383.37% in 2024.
  • Over 5 years, Cash from Operations stood at 21858000.0 in 2021, then grew by 9.89% to 19696000.0 in 2022, then fell by 17.58% to 23158000.0 in 2023, then increased by 27.62% to 16761000.0 in 2024, then fell by 0.22% to 16798000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 16798000.0, 14190000.0, and 13820000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.